koto_feja/E+ via Getty Images ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in developing treatments for central nervous system [CNS] conditions. The company has two successful FDA-approved commercial franchises, Nuplazid (pimavanserin), approved in 2016 for Parkinson’s disease psychosis, and Daybue (trofinetide), approved in March 2023 for Rett syndrome. Despite a setback with a failed clinical trial for a new indication for Nuplazid as a treatment for schizophrenia, ...